Our leadership

This is our team, a lot of  hard working people reaching new heights in clinical research.

CenExel Leadership

Tom Wardle

Chief Executive Officer

Tom has a diverse background with 33 years of progressive responsibility in pharmaceutical R&D and healthcare. He is the CEO and member of the Board of Directors of CenExel Clinical Research, the premier network of clinical research sites with expertise in Analgesia, Psychiatry, Neurology, Early Phase patient populations and Japanese bridging studies. Tom was previously the CEO of eStudySite, a leading network of clinical research sites in Infectious Disease pharmaceutical drug development.

Tom was the Chief Operating Officer of Worldwide Clinical Trials (WCT), a full service, phase I-IV global contract research organization with operations in more than 40 countries. At its founding, Tom was instrumental in identifying and evaluating acquisition targets, leading to five CRO acquisitions, followed by aggressive and successful integration in to a single platform. Subsequently, the company grew organically from 400 employees to more 1,400 employees.

From 1997 to 2007, Tom held executive management positions at two other global contract research organizations, which are now part of Syneos Health.
From 1988 to 1997 Tom was the Operations Manager at California Clinical Trials, one of the largest Phase I–III investigational sites which specialized in sophisticated clinical pharmacology studies of CNS medications. He also had management oversight of International Clinical Trials in London, England. Tom has an undergraduate degree in Exercise Physiology from BYU, a Master of Science in Kinesiology from UCLA and a Master of Business Administration (Finance) from Rutgers University.

Todd Orullian

Chief Financial Officer

Todd Orullian serves as the Cenexel Chief Financial Officer.  He is a strong senior executive with many years of finance, accounting, and operational experience. Todd is a highly self-motivated individual with a proven track record of success and exceptional performance in corporate strategy and execution. He is a results-oriented professional with a strong work ethic.

Todd has spent the last 20+ years as a CFO primarily with companies providing services to the healthcare industry.  These companies include Nelson Laboratories, AAPC, The MGIS Companies, and Professional Staff Management, Inc.  His problem-solving abilities have helped companies overcome growth challenges, improve business operations, and enhance profitability. He has an extensive background in mergers & acquisitions and in leading all aspects of finance for many organizations.  Before joining the corporate world, Todd was an audit manager for the international public accounting firm of Ernst & Young where he worked with many pre-eminent clients of the firm.

Born in Salt Lake City, Todd attended the University of Utah, where he earned his Bachelor of Science degree in Accounting, graduated Summa cum laude and was selected as the Outstanding Scholar of the School of Accounting. He then obtained his MBA from the University of Utah where he was the Dean’s Scholar and recipient of the UACPA Outstanding Graduate Student award. He is a member of the American Institute of Certified Public Accountants.

Kevin Quinn

VP of Business Development and Integration

Kevin has 25+ years of experience in medical devices and healthcare services. He has successfully achieved aggressive business objectives through effective leadership, skillful product development, market analysis, and negotiation of strategic partnerships. Prior to CenExel, Kevin was the COO of Webster portfolio company HQRC Management, a pediatric dental practice in the Northeast. At HQRC, Kevin led the practice’s expansion from 6 locations to 13 locations in 18 months through both acquisitions and de novos. He has also held prior roles as the VP of Sales/Marketing at ActivStyle Minneapolis, a medical equipment company, and Optigen, a DME business focused on treatment for sleep apnea.

Kevin was founder of EyeTel Imaging, a devise enabled service company that provided screening for diabetic retinopathy in the primary care setting. He was responsible for the development and clinical testing of a semi-automated digital fundus camera, established manufacturing in China, signed a strategic alliance with a top 10 pharma company, negotiated provider agreements with 21 of the top 22 managed health plans in the US and established a telemedicine retinal reading center in collaboration with Johns Hopkins Wilmer Eye Institute.

He has also held prior executive roles in private equity backed companies in a consumer focused DME business, a home sleep testing for Sleep Apnea and, a medical equipment company, focused on treatment for sleep apnea in the military. Kevin began his career with The Upjohn Company in sales and marketing.

Centers of Excellence Leadership

Patrick McLaughlin

CEO, Anaheim Clinical Trials

Patrick McLaughlin graduated with a degree in Business Administration from the University of Texas-Austin in 1999. Patrick’s entry into the Clinical Research space was in 1996, when he was recruited to a full-service multi-specialty dedicated research site, as President. Three years into the position at the Institute of Clinical Research (ICR), sales were up 600% and the ownership group desired to sell the company.

In March of 1999, Patrick was the principal negotiator in arranging a deal that sold ICR to Protocare, a Site Management Organization. Protocare named ICR as one of their premier sites in Centerwatch and one in which other Protocare sites would be modeled after. Shortly after the sale, Protocare was acquired by Radiant Research and ICR to this day is one of Radiant’s leading sites nearly 23 years after its acquisition.

In May of 1999, Patrick started working at Advanced Clinical Research Institute in Anaheim, CA as its Executive Director. Exclusively conducting Phase 2-4 studies for its entire history Patrick made a decision for the company to enter the Phase I sector. Dr. Dennis Riff and Patrick McLaughlin funded the purchase of an 8,800 square foot dedicated Phase I facility in 2007, and re-branded the company to its current name of Anaheim Clinical Trials.

Through years of continued success and the need for additional investment in order to move the company to the next level and to a much larger state of the art research facility, a decision was made to bring on an additional investment partner which was completed in February 2019.

Patrick is now the CEO of Anaheim Clinical Trials a division of CenExel Clinical Research.

Eric J. Riesenberg, CPA

CEO, Atlanta Center for Medical Research

Mr. Riesenberg is the Chief Executive Officer for the Atlanta Center for Medical Research. Overseeing all employees and Investigators, he is involved in every aspect of day-to-day operations at ACMR. Mr. Riesenberg has been an advisor to the board since 2001. He became director of operations in 2008.

Mr. Riesenberg currently serves on the board of advisors to the Metro Atlanta Chamber of Commerce and sits on the Bioscience Leadership Council. He is a member of the American Israel Chamber for Commerce and sits on the medical committee. He also serves on the board of Southern Surplus Liquidators, Inc., a liquidations company in Florida and Georgia. He is a member of the Drug Information Association (DIA) and American Society of Clinical Psychopharmacology (ASCP).

Mr. Riesenberg has served as a past board member to the Florida Department of Children and Family Services. Prior to joining ACMR, Mr. Riesenberg worked in the field of public accounting, where he worked with many public companies in both audits and taxes. He holds a degree in accounting from Florida Atlantic University and is a Certified Public Accountant (CPA).

Barton P. Azwalinsky

CEO, CBH Health

Mr. Azwalinsky is co-founder of CBH Health and he oversees the operations and business development activities of CBH Health. Mr. Azwalinsky has more than 30 years of experience in the delivery of community mental health services. As a leader of CBH Health, he is focused on growth and flawless delivery of clinical trials services. Mr. Azwalinsky has extensive experience in strategic planning that helps ensure CBH Health excels in the service delivery to the sponsors.

Prior to his involvement with CBH Health, Mr. Azwalinsky established and was Executive Director of Mar-Lyn residential rehabilitation program (RRP). In addition, he was President and Principal of Evergreen Mental Health Services. Mr. Azwalinsky graduated from the School of Business, University of Baltimore.

Todd Bertoch, MD

Chair, CenExel Analgesic Advisory Board
Chief Medical Officer, JBR Clinical Research

Dr. Todd Bertoch is board-certified in Anesthesiology by the American Board of Anesthesiology. He received a Bachelor of Science Degree in Biochemistry from California State University at Fullerton and a Doctor of Medicine degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland. After an internship in Internal Medicine, he completed his Anesthesiology residency at Wilford Hall Medical Center in San Antonio, Texas, where he was Chief Resident and received the Arthur B. Tarrow Outstanding Resident Award. He is a member of the esteemed Alpha Omega Alpha Honor Medical Society.

Dr. Bertoch served as an anesthesiologist in the United States Air Force until 2006. Following the terrorist attacks of September 11, 2001, Dr. Bertoch was deployed to Mindanao in the southern Philippines and later to Balad Air Base in Iraq in support of Operation Enduring Freedom. He is a recipient of the Air Force Achievement Medal, the Air Force Commendation Medal, and the Meritorious Service Medal.

After completing his military service, Dr. Bertoch served for 11 years as the managing partner of Prescott Anesthesia in Prescott, Arizona where his practice included a focus on chronic pain management and addiction medicine. He joined JBR Clinical Research as Chief Scientific Officer in 2017.

© 2019 CenExel Clinical Research        CAREERSLEGALPRIVACY POLICY